Sector News

Genzyme cuts staff and announces $845m gene therapy pact

February 13, 2015
Life sciences
Sanofi’s Genzyme unit has made a major play in the gene therapy sector with a $845m alliance with Voyager Therapeutics. 
 
The announcement was made on the same day that the company unveiled 100 job cuts at its Cambridge, Massachusetts, R&D facility, including the elimination of groups focusing on cancer and certain rare diseases. 
 
The collaboration with Voyager is focusing on the develop of gene therapies based on adeno-associated virus (AAV) vectors and intended to treat central nervous system (CNS) disorders, according to the two companies. 
 
Initial targets will be Parkinson’s disease – including Voyager’s lead product candidate VY-AADC01 which has cleared preliminary clinical trials – as well as preclinical projects Friedrich’s ataxia and Huntington’s disease. Voyager is retaining rights to a programme in amyotrophic lateral sclerosis (ALS), which is also in preclinical development.
 
Genzyme is making an upfront payment of $100m to Voyager – made up of $65m in cash, a $30m equity investment and other contributions – and the gene therapy is also in line to receive development and sales milestones of up to $745m if the partnered programmes proceed as expected in the coming years. 
 
It is a major development for a company that was only launched last year with $45m in financing from venture capital firm Third Rock Ventures.
 
Genzyme brings its own expertise in gene therapy to the alliance, having been working in that area for “more than 20 years”, according to chief executive David Meeker. The company has an AAV-based gene therapy for age-related macular degeneration (AMD) in phase I trials and is also researching gene therapies for neurologic diseases, including Huntington’s.
 
“This strategic collaboration provides significant funding to drive the development of our expanded product pipeline, while also allowing Voyager to continue to thrive as an independent company,” said Steven Paul, Voyager’s CEO.
 
Oncology changes
Meanwhile, the layoffs in Cambridge include Tal Zacks, senior vice president and head of Sanofi’s global oncology division, according to a Bloomberg report, which notes that the oncology research conducted by Zacks’ team will be transferred to other R&D units in the group.
 
Sanofi made a concerted effort to build its oncology business in 2009 but has yet to reap any significant benefit from the effort.
 
The announcements come as Sanofi is still searching for a replacement for former chief executive Chris Viehbacher, who was fired last October after clashes with the company’s board of directors. 
 
Investors have become increasingly disillusioned about the as-yet fruitless search for a replacement, and Chairman Serge Weinberg said recently that a new CEO would be named by the end of March.
 
Source: PMLive

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend